Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Cooper Companies' (COO) Unit Assigns Vuzix M400 Smart Glasses

Published 03/22/2021, 06:19 AM
Updated 07/09/2023, 06:31 AM

The Cooper Companies Inc.’s COO unit, CooperVision, recently deployed Vuzix (NASDAQ:VUZI) M400 Smart Glasses with LogistiVIEW’s Vision+ augmented reality (AR) warehouse software that will aid in hands-free picking guidance at the company’s upstate New York distribution center. Notably, this distribution site can store above 120,000 different contact lens products at any given period.

It is worth mentioning that Vuzix Corporation VUZI is a renowned supplier of Smart Glasses and AR technology products.

This announcement is likely to give a boost to CooperVision’s prospects with respect to its market position in specialty lenses.

More on the News

LogistiVIEW’s Vision+ Software Automation Platform brings together the best of traditional picking tools that include gesture control, voice interaction in a single system. Artificial Intelligence (AI) and computer vision provide intelligence to the process, thereby streamlining tasks and picking sequence to get the best efficiency.




Equipped with a hands-free solution, CooperVision can enhance the efficiency and accuracy of operations.

Market Prospects

Per a report by Grand View Research, the global smart glass market was worth $4.5 billion in 2020 and is anticipated to reach $7.5 billion by 2028, at a CAGR of 6.8% during the forecast period.

Hence, this announcement is a well-timed one for Cooper Companies.

Recent Development

In February, Cooper Companies and EssilorLuxottica – two of the world’s leading vision care companies – inked a deal to create a 50/50 joint venture for the buyout of U.S.-based life sciences company, SightGlass Vision. Notably, SightGlass Vision is focused on building innovative spectacle lenses to lower the progression of myopia in children.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Price Performance

Shares of this Zacks Rank #2 (Buy) company have gained 5.7% on a year-to-date basis compared with the industry’s growth of 4.2%.

Other Stocks to Consider

Two other same-ranked stocks from the broader medical space are Hologic (NASDAQ:HOLX), Inc. HOLX and IDEXX Laboratories, Inc. IDXX, both carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Hologic’s long-term earnings growth rate is estimated at 15.4%.

IDEXX’s long-term earnings growth rate is projected at 15.8%.

Zacks Top 10 Stocks for 2021

In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?

Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2021 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Hologic, Inc. (HOLX): Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX): Free Stock Analysis Report

Vuzix Corporation (VUZI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.